News
08-28-2017, 04:20 AM
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.
More... (https://www.news-medical.net/news/20170828/Simultaneous-treatment-with-anti-PD1-and-anti-OX40-cancer-therapies-may-have-detrimental-effect.aspx)
More... (https://www.news-medical.net/news/20170828/Simultaneous-treatment-with-anti-PD1-and-anti-OX40-cancer-therapies-may-have-detrimental-effect.aspx)